bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract C72: Social norms, family communication, and hepatitis B screening among Asian Americans
Authors: Juon Hee-Soon , Rimal Rajiv , Lee Sunmin 
Published: March 2017

Abstract
Background: Although social norms are thought to play an important role in hepatitis B screening behaviors, limited theoretical or empirical guidance exists on how the underlying process works. Using the theory of normative social behavior (TNSB), we examined the role played by injunctive norms and interpersonal discussion in the relationship between descriptive norms and hepatitis B screening behavior among Asian Americans.
Methods: Chinese, Korean, and Vietnamese Americans in the Washington D.C.-Baltimore metropolitan area (N=877) were recruited from community-based organizations. Self-administered baseline surveys collected information on their demographic, social norms (e.g., descriptive and injunctive norms), interpersonal communication, and HBV screening behavior.
Results: Social norms and family communication emerged as key factors in HBV screening. For Vietnamese Americans, family communication moderated the influence of descriptive norms on behavior. Injunctive norm moderated the influence of descriptive norms on behavior among Korean Americans. However, there was no significant interaction for Chinese Americans.
Discussion: Family communication and social Snorms are integral in enabling Asian Americans to have HBV screening and warrant sensitivity in the design of liver cancer prevention program in this high risk group of Asian Americans.
Citation Format: Hee-Soon Juon, Rajiv Rimal, Sunmin Lee. Social norms, family communication, and hepatitis B screening among Asian Americans. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr C72.
Abstract C92: [Advocate Abstract:] The Disparity of Human Papillomavirus Vaccination Knowledge, Attitudes and Practices in College-Age Women 18-26 years old
Authors: Weaks Francesca 
Published: March 2017

Abstract
Background: In 2006, two vaccinations with guidelines were released to prevent against the Human Papillomavirus (HPV), and was recommended for all females' ages 11-12. Updated guidelines target females ages 11-12, and encourage catch up vaccinations for ages 13-26. The original recommendations by the CDC and other medical professionals did not address females ages 14-26. In 2006, females ages 14-26 were not recommended to receive the vaccination but were and still are the highest risk population for contracting HPV. During the ages of 14-26 years old, most females begin sexual intercourse and become vulnerable to sexually transmitted diseases Objective: To investigate the key factors that contributes to college-aged students initiating and completing the HPV vaccination. Participants: College students ages 18-26 attending Towson University enrolled in selected Health Science Classes during Summer Session 2012. Methods: Data were collected during the summer session of 2012 from students enrolled in Health Science classes at Towson University Department of Health Science. Classes were selected from the available summer classes that were offered and had approval from the professor .Students completed a survey regarding their Knowledge, Attitudes, and Practices of HPV either during an in-class session or via Blackboard. Statistical analysis was conducted using chi-square, independent t-test, and logistic regression.
Citation Format: Francesca Weaks. [Advocate Abstract:] The Disparity of Human Papillomavirus Vaccination Knowledge, Attitudes and Practices in College-Age Women 18-26 years old. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr C92.
Abstract IA02: A global perspective on clinical cancer genomics
Authors: Weitzel Jeffrey 
Published: March 2017

Abstract
Access to genomic cancer risk assessment (GCRA) is standard of care in most developed countries, but is not readily available in Latin America. Following needs assessment, a dissemination and implementation intervention, including clinical training and application of in expensive genomic tools, was used to develop a model for vertical integration of GCRA among underserved populations in Latin America. A roundtable forum with 15 Latin American physicians representing Brazil, Colombia, Mexico, Puerto Rico and Peru was conducted to assess the state of GCRA services and barriers to implementation in these countries. The roundtable was conducted in Spanish, moderated by bilingual cancer genetics clinicians, recorded, transcribed, translated and thematically analyzed. Roundtable findings indicated a need for a multi-level approach with GCRA training, cost-effective genomic testing, and an evidence-based foundation to support the development of policy, infrastructure and resources to implement and sustain GCRA services in Latin America. The City of Hope Intensive Course and Clinical Cancer Genomics Community of Practice (CCGCoP), an NCI R25-E multi-modal training and practice support program, was piloted to address in part the need for clinicians with GCRA skills as part of infrastructure development. A common prospective registry protocol was implemented via the Cancer Genomics Community Research Network (CCGCRN), and disruptive technologies (next generation sequencing and other rapidly evolving genomic tools) enabled inexpensive BRCA testing tools to be introduced to support GCRA services. Site assessments and clinical proctoring demonstrated successful initiation of GCRA services and has revealed barriers to follow up care. Thus, innovative pairing of disruptive technologies and multimodal training tools have the potential to accelerate implementation of genomic cancer risk assessment and prevention for underserved populations.
Citation Format: Jeffrey Weitzel. A global perspective on clinical cancer genomics. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr IA02.
Abstract IA10: Cancer: A Hispanic historical perspective
Authors: Ramirez Amelie G. 
Published: March 2017

Abstract
US Hispanics/Latinos are an extremely diverse population. This diversity stems from Spanish settlements in the US in the 1400s to late 1700s, and also major immigration patterns into the US from the early 1800s to present. This means US Hispanics/Latinos differ greatly in regards to their genetic ancestry, creating variability in genetic make-up, cultural values, degree of assimilation to U.S. lifestyle, and socio-demographics. Due to the cancer health disparities that affect US Hispanics/Latinos in diverse ways, there is a tremendous need to conduct cancer research that considers US Hispanics/Latinos as a highly heterogenous population with as much diversity within, as across other ethnic groups. Certain cancer health disparities affect certain US Hispanics/Latinos ethno-regional groups differently, such as Puerto Ricans, Cubans, Mexicans, South Americans, and Central Americans. This presentation will briefly introduce data and statistics on the diversity among the US Hispanics/Latinos population and how they vary in cancer rates and cancer knowledge and attitudes, as well as emerging research.
Citation Format: Amelie G. Ramirez. Cancer: A Hispanic historical perspective. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr IA10.
Abstract IA12: Variation in genetic ancestry proportions among Latinos and its impact on cancer risk, prediction, and outcomes
Authors: Fejerman Laura 
Published: March 2017

Abstract
Latinos are a heterogeneous group, encompassing individuals with diverse genetic and sociocultural backgrounds. Reports on U.S. cancer incidence rates and cancer mortality in Latinos have only recently started to provide information by national origin, which has unveiled disparities that were not apparent in analyses that grouped all Latinos together. Genetic ancestry is another important factor in the characterization of Latin American populations. Mainly composed of European, Indigenous American and African ancestral influences, it can reflect socioeconomic/sociocultural differences as well as genetic ones. There have been studies testing the association between genetic ancestry and cancer risk, and genetic ancestry and cancer survival. However, there is a lack of published investigations assessing the performance of cancer risk prediction models in Latinos with different ancestry proportions. In this presentation, I will provide an overview of what we know about cancer risk and mortality in Latinos with different ancestry proportions and present preliminary results of an ongoing study of breast cancer risk prediction in U.S. Latinas.
Citation Format: Laura Fejerman. Variation in genetic ancestry proportions among Latinos and its impact on cancer risk, prediction, and outcomes. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr IA12.
Abstract IA32: Policy and Environmental Strategies to Reduce Cancer Risk Factors in Tribal Nations: Challenges and Opportunities
Authors: Jernigan Valarie Blue Bird 
Published: March 2017

Abstract
Cancer is a pressing public health and economic concern in Native American Tribal Nations. The Institute of Medicine has identified policy and environmental interventions (e.g., calorie labeling, smoking bans) as critical to reducing and controlling cancer risk factors, particularly obesity and tobacco use. Because of their sovereign status, Tribal Nations are uniquely positioned to implement such interventions, yet few have been reported upon in the scientific literature, hindering the scale-up and dissemination of effective interventions and even worsening disparities. This presentation will identify the current status and impact of policy and environmental interventions to address and control obesity and smoking in Native American Nations, identify and discuss barriers, what is gaining momentum, and what can be done to move toward action.
Citation Format: Valarie Blue Bird Jernigan. Policy and Environmental Strategies to Reduce Cancer Risk Factors in Tribal Nations: Challenges and Opportunities. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr IA32.
Abstract IA36: Caught in the middle: Viewing adolescent/young adult oncology patients as the medically underserved
Authors: McEachron Troy A. 
Published: March 2017

Abstract
Traditionally cancer has been thought to arise in two distinct age groups, pediatrics and adults. In the United States, pediatric patients range in age from newborn up to 21 years old while adult patients are considered to be older than 21. Recently a new patient population has begun to emerge, collectively known as the adolescent-young adult (AYA) population. In the United States, AYA patients span the age range from 15-39 years old. Much is known about a variety of “adult” cancers and our understanding of “pediatric” cancers is steadily growing. Despite these advances, there is very little data regarding AYA-specific cancers. Furthermore, the differences in normal human development and/or maturation that are encompassed within the AYA age range is extremely dynamic thus leading to the hypothesis that the molecular and clinical characteristics of malignancies in AYA patients may be inherently different than those which are observed in patients outside of this age range. This talk will highlight some of the unique challenges faced by this medically underserved population as it pertains to cancer care, treatment, and outcome. This talk will also focus on the importance of the AYA oncology population to cancer research and our biological understanding of different malignancies as it pertains to precision medicine and subsequent therapeutic strategies.
Citation Format: Troy A. McEachron. Caught in the middle: Viewing adolescent/young adult oncology patients as the medically underserved. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr IA36.
Abstract IA39: Variations in breast cancer risk by race/ethnicity in the US
Authors: DeSantis Carol 
Published: March 2017

Abstract
The American Cancer Society recommends average-risk women begin annual screening at age 45, with an option for women to begin screening earlier at age 40. This guideline is for all women; however, breast cancer risk varies substantially by race/ethnicity in the US. In this presentation, I will provide an overview of the most current information on breast cancer rates in the US, focusing on differences in risk by race/ethnicity and age, as well as for specific breast cancer subtypes.
Citation Format: Carol DeSantis. Variations in breast cancer risk by race/ethnicity in the US. [abstract]. In: Proceedings of the Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2016 Sep 25-28; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(2 Suppl):Abstract nr IA39.
Abstract A12: Developing PDeX (Patient Derived Explant) to determine the basis for response to AR-directed therapeutics
Authors: Shafi Ayesha , Schiewer Matthew , Leeuw Renee de , McCue Peter , Birbe Ruth , Gomella Leonard , Lallas Costas , Trabulsi Edouard , Raj Ganesh , Knudsen Karen 
Published: March 2017

Abstract
Prostate cancer (PCa) is the most common non-cutanenous cancer and the second leading cause of cancer-related death in American men. Androgen receptor (AR) is a hormone-activated transcription factor that plays an important role in both the development and progression of PCa. Androgen deprivation therapy is a common first-line therapy. However, many patients become resistant to such therapy and the tumor recurs. Thus, there is a vital need for the development of novel, more effective drugs. One major hurdle in this aspect is the lack of adequate preclinical models. Current models do not effectively recapitulate the heterogeneity and the microenvironment of human PCa tumors hindering the ability to accurately predict therapeutic response. Our lab has generated a method to culture patient tumors ex vivo termed patient derived explant (PDeX). This approach maintains the integrity of the native tumor microenvironment, tumor tissue morphology, and molecular signaling. Intriguingly, our PDEX model can be targeted with various therapeutic agents or lentiviral-based shRNAs to determine specific responses on individual tumor growth. Furthermore, with this model we can quantitatively assess drug efficacy on numerous parameters (i.e. AR levels, Ki67 staining, apoptosis screening). Data to be discussed will assess the variances in response to AR-directed therapeutics and underlying mechanisms of action. In addition, we can potentially identify clinically relevant subpopulations of patients and molecularly profile their cultured tissue to uncover new pathways for therapeutic intervention. Thus, the PDeX model allows for a comprehensive evaluation of individual tumors in their native microenvironment to ultimately develop more effective therapies.
Citation Format: Ayesha Shafi, Matthew Schiewer, Renee de Leeuw, Peter McCue, Ruth Birbe, Leonard Gomella, Costas Lallas, Edouard Trabulsi, Ganesh Raj, Karen Knudsen. Developing PDeX (Patient Derived Explant) to determine the basis for response to AR-directed therapeutics. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr A12.
Abstract A18: High-content 3D image analysis of patient-derived organoids
Authors: Spiller Erin , Lau Roy , Choung Sarah , Mumenthaler Shannon M. 
Published: March 2017

Abstract
Organoids are an emerging model system that more closely recapitulates the in vivo environment compared to traditional monolayer systems. Using patient-derived samples grown in a 3D matrix, we hope to advance personalized medicine by providing more patient-specific treatment plans. We have begun building a patient-derived organoid library from primary colon cancer tumors and metastases. Once cells are isolated and seeded into a Basement Membrane Extract (BME) matrix we analyze features on a high content imaging platform, the Operetta (Perkin Elmer). Using the Operetta we are able to obtain quantitative phenotypic data that includes the number, size, and morphology of organoids. In addition, we can capture the dynamics of organoid formation, growth, and death by tracking the same organoids over time using live-cell imaging.
More specifically, for each organoid, we capture z-stack images at various heights, and using the Harmony software, we perform quantitative analysis on the maximum projection of the complied images. Using a building block approach, we created a workflow that first relied on identifying regions of interest (ROI), which correspond to organoids. In each ROI we then obtained information such as geometric center, length and width measurements, and texture features. We used this information to determine inter-patient heterogeneity, as well as differences across samples isolated from the primary location (i.e. colon) versus metastatic sites (i.e. liver). After culturing patient-derived organoids for several weeks in laboratory conditions, we perturbed various aspects of the tumor microenvironment (e.g. drug and oxygen levels) and subsequently tracked changes in organoid number, size, and morphology over time. This workflow represents a unique method for image-based quantitative phenotypic analysis of organoids under varying environmental conditions.
Citation Format: Erin Spiller, Roy Lau, Sarah Choung, Shannon M. Mumenthaler. High-content 3D image analysis of patient-derived organoids. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr A18.
Abstract IA10: Renal cancer tumorgrafts: A validated model to evaluate novel targeted therapies
Authors: Pavia-Jimenez Andrea , Chen Wenfang , Hill Haley , Christie Alana , Yousuf Qurratulain , Williams Noelle , Xie Xian-Jin , Kapur Payal , Brugarolas James 
Published: March 2017

Abstract
Renal cell carcinoma (RCC) is diagnosed in over 50,000 Americans annually and in the metastatic setting remains largely incurable. The development of new drugs is hampered by the lack of suitable preclinical animal models reproducing the characteristics of human tumors. To date, we have implanted tumors from over 700 kidney cancer patients orthotopically in mice. Our models include common tumor types, such as clear cell and papillary, but also rare tumor types such as translocation carcinomas and fumarate hydratase (FH)-deficient renal tumors from HLRCC patients. We have shown that tumor fragments implanted orthotopically into NOD/SCID mice result in tumors that reproduce: (i) histology, (ii) gene expression, (iii) DNA copy number alterations and (iv) mutations. Tumorgraft (TG)-bearing mice also reproduce paraneoplastic syndromes (paraneoplastic hypercalcemia). Furthermore, TGs recapitulate the treatment responsiveness of RCC in patients. We performed pharmacokinetic studies to determine appropriate administration regimens resulting in comparable exposures. TGs responded to drugs effective against RCC in patients (sunitinib and sirolimus, which accounts for 70% of the circulating drug after temsirolimus administration) and were resistant to ineffective drugs (erlotinib). TGs provide a superb platform to evaluate promising novel therapeutics. Data will be presented on the application of our TG platform to the evaluation of a first-in-class inhibitor of arguably the most important driver of RCC, the HIF-2 transcription factor. TGs were used to assess activity, validate a putative pharmacodynamic biomarker, identify biomarkers of sensitivity, and to assess the development of resistance. By leveraging a large and diverse TG platform, preclinical drug testing may be rigorously conducted, the most promising agents may be identified, and future clinical development may be effectively informed.
Citation Format: Andrea Pavia-Jimenez, Wenfang Chen, Haley Hill, Alana Christie, Qurratulain Yousuf, Noelle Williams, Xian-Jin Xie, Payal Kapur, James Brugarolas. Renal cancer tumorgrafts: A validated model to evaluate novel targeted therapies. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr IA10.